C-Path receives letter of support from EMA on type 1 diabetes biomarker initiative

TUCSON, Ariz., April 28, 2020 –The Critical Path Institute (C-Path) today announced that its Type 1 Diabetes (T1D) Consortium has received a letter of support from the European Medicines Agency (EMA) to facilitate the development and validation of the proposed regulatory qualification of pancreatic islet autoantibodies commonly used in clinical practice to diagnose T1D: insulin…

Details